|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2004-3-5
|
|
pubmed:abstractText |
Treatment of visceral leishmaniasis in HIV patients encounters inefficacy and relapse due to drug resistance, toxicity and immunodepression. Our goal was to evaluate treatment of these patients by liposomal amphotericin B (L-AmB). Since 1998, five clinical files were exploitable out of 13 patients. Protocols used bolus doses ranging between 2.9 and 4.1 mg/kg dispatched on 5-24 days, followed by maintenance dose ranging from 2.7 to 3.8 mg/kg every 15 days. Attack treatment involved high bolus dose (cumulated doses ranging from 60 to 86 mg/kg at day 30) and allowed favorable clinical and biological results with healing in four patients. Secondary prophylaxis with L-AmB has been efficacious and well tolerated in three patients. Although literature and study results cannot indicate a standard therapeutic care in these patients, an initial treatment by L-AmB at doses higher than marketing-approved doses with a secondary prophylaxis by L-AmB associated with an antiretroviral treatment seem to be major asset in order to obtain healing. Expanding this study to a multicenter trial should allow to better define the frequency and duration of the secondary prophylaxis and to evaluate the risk of therapeutic escape as well as the life-span increase.
|
|
pubmed:language |
fre
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0369-8114
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
52
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
66-75
|
|
pubmed:dateRevised |
2008-9-25
|
|
pubmed:meshHeading |
pubmed-meshheading:15001234-Adult,
pubmed-meshheading:15001234-Amphotericin B,
pubmed-meshheading:15001234-Animals,
pubmed-meshheading:15001234-Antiprotozoal Agents,
pubmed-meshheading:15001234-Drug Combinations,
pubmed-meshheading:15001234-Drug Evaluation,
pubmed-meshheading:15001234-Female,
pubmed-meshheading:15001234-HIV Infections,
pubmed-meshheading:15001234-Humans,
pubmed-meshheading:15001234-Leishmania infantum,
pubmed-meshheading:15001234-Leishmaniasis, Visceral,
pubmed-meshheading:15001234-Male,
pubmed-meshheading:15001234-Meglumine,
pubmed-meshheading:15001234-Organometallic Compounds,
pubmed-meshheading:15001234-Phosphatidylcholines,
pubmed-meshheading:15001234-Phosphatidylglycerols,
pubmed-meshheading:15001234-Recurrence,
pubmed-meshheading:15001234-Retrospective Studies,
pubmed-meshheading:15001234-Substance Abuse, Intravenous,
pubmed-meshheading:15001234-Treatment Outcome
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
[Liposomal amphotericin B in secondary prophylaxis of visceral leishmaniasis in HIV-infected patients: report of five clinical cases].
|
|
pubmed:affiliation |
Pharmacie, CHU de la Conception, 147, boulevard Baille, 13005 Marseille, France. montanamarc@hotmail.com
|
|
pubmed:publicationType |
Journal Article,
English Abstract,
Review
|
